Using a new form of CD4-Ig to fight viral infections
Therapeutic use of an enhanced form of CD4-Ig
This study is looking at a new way to deliver a treatment that could help protect people from certain viral infections for a long time, using a special virus to carry it, and it's being tested in animals to see if it could eventually work for humans.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston Children's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10991023 on NIH RePORTER |
What this research studies
This research investigates an enhanced version of CD4-Ig, which is delivered using adeno-associated viruses (AAV) to provide long-term protection against certain viral infections. The approach focuses on optimizing the delivery and expression of eCD4-Ig to overcome challenges such as immune clearance and viral escape. By studying its effects in animal models, the research aims to develop a potential functional cure for viral infections that could also be applicable to humans.
Who could benefit from this research
Good fit: Ideal candidates for this research would include individuals with chronic viral infections, particularly those who may benefit from innovative therapeutic approaches.
Not a fit: Patients with acute viral infections or those who do not have chronic viral conditions may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment that provides long-lasting protection against viral infections, potentially reducing the need for ongoing antiretroviral therapies.
How similar studies have performed: Other research has shown promise with similar AAV-mediated delivery approaches, indicating potential for success in this area.
Where this research is happening
Boston, United States
- Boston Children's Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Farzan, Michael R. — Boston Children's Hospital
- Study coordinator: Farzan, Michael R.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.